ASPEN PHARMACARE HOLDINGS LIMITED - ACQUISITION OF RIGHTS TO AN ANTI-COAGULENT PRODUCT FROM NOVARTIS

ACQUISITION OF RIGHTS TO AN ANTI-COAGULENT PRODUCT FROM NOVARTIS

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
and its subsidiaries (collectively “Aspen” or “the Group”)



ACQUISITION OF RIGHTS TO AN ANTI-COAGULENT PRODUCT FROM NOVARTIS

Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of
Aspen Holdings, has entered into an agreement with Novartis AG in terms of which it will acquire
the rights to Mono-Embolex®, an injectable anti-coagulant, for a consideration of US$142.3 million.

Mono-Embolex is a heparin based anti-coagulant sold in the same therapeutic category as Aspen’s
Arixtra and Fraxiparine. This product is, however, the only low molecular weight heparin that offers
patients weight-independent dosing, thereby combining ease of administration with the proven
efficacy in prophylaxis and therapy of deep vein thrombosis.

The product presents an excellent strategic fit with the Group’s recent acquisitions in this
therapeutic area and will be positioned as a simple-to-use once daily prophylaxis treatment
supporting Aspen’s other current anti-coagulant offerings. As the product is only commercialized in
Germany, Switzerland and Austria it presents Aspen with an opportunity to launch it in other
countries. The product recorded revenue of EUR68 million in 2013.

The transaction is subject to the approval of the German competition authorities.



Durban

23 January 2015

Sponsor:

Investec Bank Limited

Date: 23/01/2015 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.